Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nomita Joshi

Internal Medicine Mauldin, SC Medical Doctor

NPI 1104865575 CMS profile 276544

213 E Butler Road, Building C-1, Mauldin, SC 29662

Open in the dashboard

General payments

$5,308

243 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nomita Joshi of Mauldin, SC is reported in the CMS Open Payments database as having received $5,308 across 243 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $412 14
2024 General $1,003 35
2023 General $792 45
2022 General $601 35
2021 General $1,228 49
2020 General $704 38
2019 General $568 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nomita Joshi
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Nomita Joshi were reported at $412. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Nomita Joshi Internal Medicine median Middle half National median
2019 $568 $159 $48–$570 $163
2020 $704 $119 $33–$402 $114
2021 $1,228 $135 $37–$521 $132
2022 $601 $141 $42–$496 $149
2023 $792 $149 $45–$519 $160
2024 $1,003 $154 $47–$537 $164
2025 $412 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $707 18 payments
  2. Lilly USA, LLC $663 37 payments
  3. Janssen Pharmaceuticals, Inc $642 27 payments
  4. Novo Nordisk Inc $528 23 payments
  5. AbbVie, Inc. $349 23 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $340 16 payments
  7. GlaxoSmithKline, LLC. $268 10 payments
  8. Pfizer Inc. $233 15 payments
  9. Phathom Pharmaceuticals, Inc. $194 5 payments
  10. Abbott Laboratories $185 8 payments
  11. Other $1,199 61 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,308 243 payments
Products named General payments · program years 2019–2025
  1. XARELTO $642 27 payments
  2. FARXIGA $469 12 payments
  3. Ozempic $360 18 payments
  4. Kerendia $340 16 payments
  5. RYBELSUS $226 16 payments
  6. JARDIANCE $222 13 payments
  7. BREZTRI $220 6 payments
  8. TRULICITY $199 12 payments
  9. VRAYLAR $184 6 payments
  10. VOQUEZNA $179 4 payments
  11. Other $3,342 179 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 140 drugs

Part D claims

8,461

Median for Internal Medicine: 777

Drug cost

$599,868

Median for Internal Medicine: $73,373

Branded share of claims

23.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 72 $78,256
Ozempic Semaglutide Brand 63 $78,116
Linzess Linaclotide Brand 73 $57,393
Eliquis Apixaban Brand 51 $53,610
Januvia Sitagliptin Phosphate Brand 49 $45,038
Farxiga Dapagliflozin Propanediol Brand 40 $35,999
Trulicity Dulaglutide Brand 23 $30,248
Rybelsus Semaglutide Brand 23 $23,046
Tresiba Flextouch U-200 Insulin Degludec Brand 14 $18,678
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 20 $18,012

The 10 drugs with the highest cost, of 140 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 55 billing codes

Paid by Medicare

$157,742

Of which drugs: $4,512

Medicare patients

197

Average age 69

Services billed

2,870

127 women, 70 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 44%
Chronic kidney disease 36%
Diabetes 33%
Depression 26%
Ischemic heart disease 23%
Heart failure 20%
COPD 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for pneumococcal polysaccharide for injection beneath the skin or into muscle, patient 2 years or older 90732 Office 19 19 $2,485
Influenza vaccine, trivalent derived from cell cultures 90661 Office 56 56 $1,986
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 12 32 $33

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $109
  • Lundbeck LLC $61
$170 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $165
$165 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $120
$120 — —
AREXVY
  • GlaxoSmithKline, LLC. $113
$113 — —
JARDIANCE
  • Lilly USA, LLC $53
$53 72 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

243 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record